Cargando…
Chemotherapeutics-Induced Intestinal Mucositis: Pathophysiology and Potential Treatment Strategies
The gastrointestinal tract is particularly vulnerable to off-target effects of antineoplastic drugs because intestinal epithelial cells proliferate rapidly and have a complex immunological interaction with gut microbiota. As a result, up to 40–100% of all cancer patients dosed with chemotherapeutics...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129190/ https://www.ncbi.nlm.nih.gov/pubmed/34017262 http://dx.doi.org/10.3389/fphar.2021.681417 |
_version_ | 1783694274428141568 |
---|---|
author | Dahlgren, David Sjöblom, Markus Hellström, Per M Lennernäs, Hans |
author_facet | Dahlgren, David Sjöblom, Markus Hellström, Per M Lennernäs, Hans |
author_sort | Dahlgren, David |
collection | PubMed |
description | The gastrointestinal tract is particularly vulnerable to off-target effects of antineoplastic drugs because intestinal epithelial cells proliferate rapidly and have a complex immunological interaction with gut microbiota. As a result, up to 40–100% of all cancer patients dosed with chemotherapeutics experience gut toxicity, called chemotherapeutics-induced intestinal mucositis (CIM). The condition is associated with histological changes and inflammation in the mucosa arising from stem-cell apoptosis and disturbed cellular renewal and maturation processes. In turn, this results in various pathologies, including ulceration, pain, nausea, diarrhea, and bacterial translocation sepsis. In addition to reducing patient quality-of-life, CIM often leads to dose-reduction and subsequent decrease of anticancer effect. Despite decades of experimental and clinical investigations CIM remains an unsolved clinical issue, and there is a strong consensus that effective strategies are needed for preventing and treating CIM. Recent progress in the understanding of the molecular and functional pathology of CIM had provided many new potential targets and opportunities for treatment. This review presents an overview of the functions and physiology of the healthy intestinal barrier followed by a summary of the pathophysiological mechanisms involved in the development of CIM. Finally, we highlight some pharmacological and microbial interventions that have shown potential. Conclusively, one must accept that to date no single treatment has substantially transformed the clinical management of CIM. We therefore believe that the best chance for success is to use combination treatments. An optimal combination treatment will likely include prophylactics (e.g., antibiotics/probiotics) and drugs that impact the acute phase (e.g., anti-oxidants, apoptosis inhibitors, and anti-inflammatory agents) as well as the recovery phase (e.g., stimulation of proliferation and adaptation). |
format | Online Article Text |
id | pubmed-8129190 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81291902021-05-19 Chemotherapeutics-Induced Intestinal Mucositis: Pathophysiology and Potential Treatment Strategies Dahlgren, David Sjöblom, Markus Hellström, Per M Lennernäs, Hans Front Pharmacol Pharmacology The gastrointestinal tract is particularly vulnerable to off-target effects of antineoplastic drugs because intestinal epithelial cells proliferate rapidly and have a complex immunological interaction with gut microbiota. As a result, up to 40–100% of all cancer patients dosed with chemotherapeutics experience gut toxicity, called chemotherapeutics-induced intestinal mucositis (CIM). The condition is associated with histological changes and inflammation in the mucosa arising from stem-cell apoptosis and disturbed cellular renewal and maturation processes. In turn, this results in various pathologies, including ulceration, pain, nausea, diarrhea, and bacterial translocation sepsis. In addition to reducing patient quality-of-life, CIM often leads to dose-reduction and subsequent decrease of anticancer effect. Despite decades of experimental and clinical investigations CIM remains an unsolved clinical issue, and there is a strong consensus that effective strategies are needed for preventing and treating CIM. Recent progress in the understanding of the molecular and functional pathology of CIM had provided many new potential targets and opportunities for treatment. This review presents an overview of the functions and physiology of the healthy intestinal barrier followed by a summary of the pathophysiological mechanisms involved in the development of CIM. Finally, we highlight some pharmacological and microbial interventions that have shown potential. Conclusively, one must accept that to date no single treatment has substantially transformed the clinical management of CIM. We therefore believe that the best chance for success is to use combination treatments. An optimal combination treatment will likely include prophylactics (e.g., antibiotics/probiotics) and drugs that impact the acute phase (e.g., anti-oxidants, apoptosis inhibitors, and anti-inflammatory agents) as well as the recovery phase (e.g., stimulation of proliferation and adaptation). Frontiers Media S.A. 2021-05-04 /pmc/articles/PMC8129190/ /pubmed/34017262 http://dx.doi.org/10.3389/fphar.2021.681417 Text en Copyright © 2021 Dahlgren, Sjöblom, Hellström and Lennernäs. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Dahlgren, David Sjöblom, Markus Hellström, Per M Lennernäs, Hans Chemotherapeutics-Induced Intestinal Mucositis: Pathophysiology and Potential Treatment Strategies |
title | Chemotherapeutics-Induced Intestinal Mucositis: Pathophysiology and Potential Treatment Strategies |
title_full | Chemotherapeutics-Induced Intestinal Mucositis: Pathophysiology and Potential Treatment Strategies |
title_fullStr | Chemotherapeutics-Induced Intestinal Mucositis: Pathophysiology and Potential Treatment Strategies |
title_full_unstemmed | Chemotherapeutics-Induced Intestinal Mucositis: Pathophysiology and Potential Treatment Strategies |
title_short | Chemotherapeutics-Induced Intestinal Mucositis: Pathophysiology and Potential Treatment Strategies |
title_sort | chemotherapeutics-induced intestinal mucositis: pathophysiology and potential treatment strategies |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129190/ https://www.ncbi.nlm.nih.gov/pubmed/34017262 http://dx.doi.org/10.3389/fphar.2021.681417 |
work_keys_str_mv | AT dahlgrendavid chemotherapeuticsinducedintestinalmucositispathophysiologyandpotentialtreatmentstrategies AT sjoblommarkus chemotherapeuticsinducedintestinalmucositispathophysiologyandpotentialtreatmentstrategies AT hellstromperm chemotherapeuticsinducedintestinalmucositispathophysiologyandpotentialtreatmentstrategies AT lennernashans chemotherapeuticsinducedintestinalmucositispathophysiologyandpotentialtreatmentstrategies |